Wimmer Associates 1 LLC Sells 385 Shares of Amgen Inc. (NASDAQ:AMGN)

Wimmer Associates 1 LLC decreased its holdings in Amgen Inc. (NASDAQ:AMGN) by 4.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 8,750 shares of the medical research company’s stock after selling 385 shares during the quarter. Amgen makes up 1.1% of Wimmer Associates 1 LLC’s investment portfolio, making the stock its 26th biggest holding. Wimmer Associates 1 LLC’s holdings in Amgen were worth $2,281,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the business. Beck Mack & Oliver LLC grew its stake in shares of Amgen by 0.7% in the fourth quarter. Beck Mack & Oliver LLC now owns 4,623 shares of the medical research company’s stock worth $1,205,000 after purchasing an additional 34 shares during the last quarter. Blossom Wealth Management boosted its position in Amgen by 3.5% during the fourth quarter. Blossom Wealth Management now owns 1,090 shares of the medical research company’s stock valued at $284,000 after acquiring an additional 37 shares during the last quarter. Zullo Investment Group Inc. boosted its position in Amgen by 2.8% during the fourth quarter. Zullo Investment Group Inc. now owns 1,364 shares of the medical research company’s stock valued at $356,000 after acquiring an additional 37 shares during the last quarter. Trillium Asset Management LLC boosted its position in Amgen by 4.2% during the fourth quarter. Trillium Asset Management LLC now owns 911 shares of the medical research company’s stock valued at $237,000 after acquiring an additional 37 shares during the last quarter. Finally, Evermay Wealth Management LLC raised its holdings in shares of Amgen by 1.5% during the fourth quarter. Evermay Wealth Management LLC now owns 2,650 shares of the medical research company’s stock valued at $691,000 after purchasing an additional 38 shares during the period. Institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling

In other Amgen news, EVP David M. Reese sold 25,225 shares of the stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $304.44, for a total value of $7,679,499.00. Following the sale, the executive vice president now directly owns 36,922 shares in the company, valued at $11,240,533.68. This represents a 40.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.76% of the stock is owned by insiders.

Amgen Stock Up 0.3%

Amgen stock opened at $272.41 on Monday. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The firm has a 50 day moving average price of $291.00 and a 200-day moving average price of $287.86. The company has a market capitalization of $146.48 billion, a P/E ratio of 36.08, a P/E/G ratio of 2.63 and a beta of 0.51. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, beating analysts’ consensus estimates of $4.18 by $0.72. The firm had revenue of $8.15 billion during the quarter, compared to the consensus estimate of $8.05 billion. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The company’s revenue was up 9.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.96 EPS. As a group, equities analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be issued a $2.38 dividend. This represents a $9.52 annualized dividend and a yield of 3.49%. The ex-dividend date of this dividend is Friday, May 16th. Amgen’s dividend payout ratio (DPR) is presently 86.86%.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Cantor Fitzgerald assumed coverage on shares of Amgen in a report on Tuesday, April 22nd. They set a “neutral” rating and a $305.00 price objective on the stock. Morgan Stanley restated an “equal weight” rating on shares of Amgen in a report on Friday, May 2nd. Citigroup restated a “neutral” rating on shares of Amgen in a report on Wednesday, February 5th. Mizuho upped their target price on shares of Amgen from $235.00 to $280.00 and gave the stock a “neutral” rating in a report on Wednesday, May 7th. Finally, Erste Group Bank downgraded shares of Amgen from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 8th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, Amgen presently has a consensus rating of “Hold” and an average price target of $310.18.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.